Vasiliki K Katsi, Christos A Michalakeas, Charalambos E Grassos, Georgia D Vamvakou, John P Lekakis, Dimitris Tousoulis, Christodoulos I Stefanadis, Thomas K Makris, Ioannis E Kallikazaros
{"title":"Canagliflozin: a new hope in the antidiabetic armamentarium.","authors":"Vasiliki K Katsi, Christos A Michalakeas, Charalambos E Grassos, Georgia D Vamvakou, John P Lekakis, Dimitris Tousoulis, Christodoulos I Stefanadis, Thomas K Makris, Ioannis E Kallikazaros","doi":"10.2174/1574890108666131213100613","DOIUrl":null,"url":null,"abstract":"<p><p>Canagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several phase III clinical ongoing trials involving this new class of medications. So far promising results have been shown. This review article summarizes current knowledge regarding the novel SGLT2 inhibitor canagliflozin and its future perspectives in the treatment of type 2 diabetes mellitus. </p>","PeriodicalId":20905,"journal":{"name":"Recent patents on cardiovascular drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on cardiovascular drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574890108666131213100613","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
Canagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several phase III clinical ongoing trials involving this new class of medications. So far promising results have been shown. This review article summarizes current knowledge regarding the novel SGLT2 inhibitor canagliflozin and its future perspectives in the treatment of type 2 diabetes mellitus.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
